首页> 外文期刊>Proceedings of the National Academy of Sciences of the United States of America >PIM1 gene cooperates with human BCL6 gene to promote the development of lymphomas
【24h】

PIM1 gene cooperates with human BCL6 gene to promote the development of lymphomas

机译:PIM1基因与人类BCL6基因合作促进淋巴瘤的发展

获取原文
获取原文并翻译 | 示例
       

摘要

Diffuse large B-cell lymphomas in humans are associated with chromosomal rearrangements (~40%) and/or mutations disrupting autoregulation (~16%) involving the BCL6 gene. Studies of lymphoma development in humans and mouse models have indicated that lymphomagenesis evolves through the accumulation of multiple genetic alterations. Based on our prior studies, which indicated that carcinogen-induced DNA mutations enhance the incidence of lymphomas in our mouse model expressing a human BCL6 transgene, we hypothesized that mutated genes are likely to play an important cooperative role in BCZ.6-associated lymphoma development. We used retroviral insertional mutagenesis in an effort to identify which genes cooperate with BCL6 in lymphomagenesis in our BCL6 transgenic mice. We identified PIM1 as the most frequently recurring cooperating gene in our murine BCL6-associated lymphomas (T- and B-cell types), and we observed elevated levels of PIM1 mRNA and protein expression in these neoplasms. Further, immunohistochemical staining, which was performed in 20 randomly selected BCL6-positive human B- and T-cell lymphomas, revealed concurrent expression of BCL6 and PIM1 in these neoplasms. As PIM1 encodes a serine/threonine kinase, PIM1 kinase inhibition may be a promising therapy for BCL6/ PIM1-positive human lymphomas.
机译:人中弥漫性大B细胞淋巴瘤与染色体重排(〜40%)和/或涉及BCL6基因的破坏自体调节的突变(〜16%)相关。在人类和小鼠模型中对淋巴瘤发展的研究表明,淋巴瘤的发生是通过多种基因改变的积累而演变而来的。基于我们先前的研究,该研究表明致癌物诱导的DNA突变会增加表达人BCL6转基因的小鼠模型中淋巴瘤的发生率,我们假设突变的基因可能在BCZ中起重要的协同作用。6相关淋巴瘤的发生。为了确定在我们的BCL6转基因小鼠的淋巴瘤发生中哪些基因与BCL6协同作用,我们使用了逆转录病毒插入诱变。我们确定PIM1是我们的鼠BCL6相关淋巴瘤(T细胞和B细胞类型)中最频繁出现的合作基因,并且我们观察到这些肿瘤中PIM1 mRNA和蛋白表达水平升高。此外,在20例随机选择的BCL6阳性人类B细胞和T细胞淋巴瘤中进行的免疫组织化学染色显示,在这些肿瘤中BCL6和PIM1同时表达。由于PIM1编码丝氨酸/苏氨酸激酶,因此抑制PIM1激酶可能是BCL6 / PIM1阳性人类淋巴瘤的有前途的疗法。

著录项

  • 来源
  • 作者单位

    Department of Pathology, University of Chicago, Chicago, IL 60637;

    Department of Pathology, University of Chicago, Chicago, IL 60637;

    Department of Pathology, University of Chicago, Chicago, IL 60637;

    Leukemogenesis Section, Laboratory of Cellular Oncology, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892;

    Department of Pathology, University of Chicago, Chicago, IL 60637;

    Departments of Medicine and University of Chicago, Chicago, IL 60637;

    Department of Pathology, University of Chicago, Chicago, IL 60637;

    Departments of Medicine and University of Chicago, Chicago, IL 60637;

    Departments of Health Studies, University of Chicago, Chicago, IL 60637;

    Leukemogenesis Section, Laboratory of Cellular Oncology, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892;

    Departments of Medicine and University of Chicago, Chicago, IL 60637;

  • 收录信息 美国《科学引文索引》(SCI);美国《生物学医学文摘》(MEDLINE);美国《化学文摘》(CA);
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

  • 入库时间 2022-08-18 00:40:18

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号